Sernova Biotherapeutics Inc. is a Canada-based clinical-stage company, which is focused on developing regenerative medicine therapeutics combining its Cell Pouch with human donor cells or stem cell-derived cell therapies to create bio-hybrid organs to treat chronic diseases. A bio-hybrid organ is comprised of non-biomaterials, such as the Cell Pouch, integrated with living tissues to restore or enhance the function of a compromised organ. This approach aims to deliver a potentially revolutionary treatment for patients with chronic diseases, initially focusing on type 1 diabetes (T1D) and thyroid disorders. Cell Pouch is a bio-hybrid organ which is surgically implanted beneath the skin of the abdomen.

Employees

Sector

Medical Equipment, Supplies & Distribution

More about the company

Quotes

Date	Price	Change	Volume
06/26/06	CA$0.1100	+4.76%	32,010
05/26/05	CA$0.1050	0.00%	12,124
04/26/04	CA$0.1050	-8.70%	98,464
03/26/03	CA$0.1150	+15.00%	1,49,829
02/26/02	CA$0.1000	-4.76%	39,444

End-of-day quote Toronto S.E.

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.1100CAD

Average target price

1.000CAD

Spread / Average Target

+809.09%

Consensus

EPS Estimates

Evolution of Analysts' Estimates - EPS - Sernova Biotherapeutics Inc

Revisions to estimates

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Sernova Biotherapeutics Inc

Company calendar

End-of-day quote Toronto S.E. 06/11/2026			5-day change	1st Jan Change
0.1100 ^CAD	+4.76%		+4.76%	-15.38%

11/09	Sernova Biotherapeutics Inc Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2026	CI
09/09	Seraxis Holdings, Inc. entered into a definitive agreement to acquire Sernova Biotherapeutics Inc in a merger of equals, reverse merger transaction.	CI

Market Cap	4.15Cr 2.95Cr 2.64Cr 2.42Cr 2.2Cr 276.99Cr 4.29Cr 29Cr 12Cr 147.8Cr 11Cr 11Cr 466.58Cr	P/E 2026 *	-4.4x	P/E 2027 *	-3.67x
Enterprise Value	4.15Cr 2.95Cr 2.64Cr 2.42Cr 2.2Cr 276.99Cr 4.29Cr 29Cr 12Cr 147.8Cr 11Cr 11Cr 466.58Cr	EV / Sales 2026 *	-	EV / Sales 2027 *	16.6x
Free-Float	89.49%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Toronto S.E.	SVA	End-of-day quote
Toronto S.E.	SVA	Delayed
Deutsche Boerse AG	PSH0	Delayed
Xetra	PSH0	Delayed
Tradegate	PSH0	Real-time
Boerse Muenchen	PSH0	Real-time
OTC Markets	SEOVF	Delayed
Börse Stuttgart	PSH0	Delayed

11/09	Sernova Biotherapeutics Inc Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2026	CI
09/09	Seraxis Holdings, Inc. entered into a definitive agreement to acquire Sernova Biotherapeutics Inc in a merger of equals, reverse merger transaction.	CI
17/06	Sernova's Autologous Islet Transplantation Gets Orphan Drug Designation For Type 3c Diabetes Prevention	MT
12/06	Sernova Biotherapeutics Inc Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2026	CI
23/04	Sernova Biotherapeutics Inc announced that it has received CAD 7.564399 million in funding	CI
14/03	Sernova Biotherapeutics Inc Reports Earnings Results for the First Quarter Ended January 31, 2026	CI
05/03	Sernova Biotherapeutics Inc announced that it expects to receive CAD 7.1 million in funding	CI
20/12	Sernova Biotherapeutics Inc Reports Earnings Results for the Full Year Ended October 31, 2025	CI
19/12	Sernova Biotherapeutics Inc Auditor Raises 'Going Concern' Doubt	CI
13/11	Sernova Biotherapeutics Inc announced that it expects to receive CAD 5 million in funding	CI
23/25/23	Sernova Biotherapeutics Inc Appoints John L. Brooks III as Chair of the Board of Directors	CI
16/25/16	Sernova Biotherapeutics Inc Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2025	CI
09/25/09	Sernova Partners With Eledon Pharmaceuticals to Advance Potential Functional Cure for Type 1 Diabetes	MT

Sernova Biotherapeutics Inc Share Price

Stocks

SVA

CA81752F1062

Medical Equipment, Supplies & Distribution

Valuation: Sernova Biotherapeutics Inc

Chart: Sernova Biotherapeutics Inc

Latest news: Sernova Biotherapeutics Inc

Press Releases: Sernova Biotherapeutics Inc

News in other languages: Sernova Biotherapeutics Inc

Quotes and Performance

Price Extremes

Managers and Directors: Sernova Biotherapeutics Inc

Latest insider transactions

Medical Devices & Implants

Financials

Company Profile

Quotes

Analysts' Consensus

Quarterly revenue - Rate of surprise

05/10	Sernova and Seraxis Close US$11.2 Million Financing to Fund Merger to Become BetaNova Biotherapeutics and Advance Type 1 Diabetes Cell Therapy Into Near Term Phase 1/2 Clinical Trial	AQ
25/09	Sernova Biotherapeutics to Participate in Noble Capital Markets’ Emerging Growth Virtual Equity Conference	AQ
12/09	Steven Sangha Announces Voting and Support Agreement for Sernova Biotherapeutics Inc.'s Proposed Business Combination with Seraxis Holdings, Inc.	NE
10/09	Sernova Biotherapeutics to Participate in the H.C. Wainwright 28th Annual Global Investor Conference	AQ
08/09	Sernova and Seraxis Enter Definitive Merger Agreement to Create a Differentiated Type 1 Diabetes Islet Cell-Replacement Biotech Company, BetaNova Biotherapeutics	AQ

15/23/15	Sernova-Telefonkonferenz für Investoren, die ursprünglich für den 15. September geplant war, wird nun auf den 22. September verschoben
13/23/13	Sernova veranstaltet Telefonkonferenzen für Investoren zur Vorstellung der neu ernannten CEO und zur Bekanntgabe eines Updates zur Geschäftsentwicklung
03/23/03	AstraZeneca : accord de recherche avec le canadien Sernova
03/23/03	Sernova kündigt Forschungskooperation mit dem Pharmakonzern AstraZeneca an, um neuartige potenzielle Zelltherapie-Anwendungen zu untersuchen
10/23/10	Sernova präsentiert beim 2023 Cell & Gene Meeting on the Med der Alliance for Regenerative Medicine

1 day	+4.76%
1 week	+4.76%
Current month	+4.76%
1 month	-8.33%
3 months	-4.35%
6 months	-35.29%
Current year	-15.38%

1 week	0.1	0.12
1 month	0.1	0.12
Current year	0.08	0.2
1 year	0.08	0.2
3 years	0.08	0.77
5 years	0.08	2.22
10 years	0.08	2.87

Manager	Title	Age	Since
Jonathan Rigby CEO	Chief Executive Officer	59	12/08/2024
Marie Kaldchibachi DFI	Director of Finance/CFO	-	01/11/2023
James Parsons DFI	Director of Finance/CFO	61	07/10/2024

Director	Title	Age	Since
Steven Sangha BRD	Director/Board Member	-	24/04/2023
Jonathan Rigby CHM	Chairman	59	02/06/2025
David Paterson BRD	Director/Board Member	-	01/09/2024

Date	Insider	Type	Main position	Quantity	% Market Cap.
03/07/26	SERNOVA BIOTHERAPEUTICS, INC.	Sell	Company	-1,15,000	0.0305%
22/05/26	John Brooks	Option	Chairman	2,28,912	0.0658%
22/05/26	Steven Sangha	Option	Director	2,60,000	0.0748%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SERNOVA BIOTHERAPEUTICS INC	+4.76%	+4.76%	-26.67%	-85.71%	2.95Cr
ABBOTT LABORATORIES	-3.23%	+3.51%	-13.00%	+15.96%	19TCr
MEDTRONIC PLC	-2.90%	+5.45%	+10.41%	+40.45%	12TCr
STRYKER CORPORATION	-2.75%	+11.65%	-8.47%	+18.50%	12TCr
ESSILORLUXOTTICA	+0.96%	+5.15%	-37.16%	+12.09%	9.93TCr
CENCORA, INC.	-1.80%	+0.82%	-7.52%	+70.12%	6.37TCr
BECTON, DICKINSON AND COMPANY	-0.78%	+7.07%	+19.14%	-17.27%	5.77TCr
IDEXX LABORATORIES, INC.	+0.79%	+22.65%	-4.57%	+60.02%	5.33TCr
HOYA CORPORATION	-6.98%	-14.56%	-11.97%	+46.23%	4.7TCr
ALCON INC.	-2.36%	+3.72%	+3.86%	-7.99%	3.62TCr
Average	-1.43%	+5.74%	-7.60%	+15.24%	7.96TCr
Weighted average by Cap.	-2.20%	+5.71%	-7.49%	+25.27%

	2026 *	2027 *
Net sales	-	25L 17.73L 15.91L 14.54L 13.27L 17Cr 25.79L 1.75Cr 69.86L 8.89Cr 66.56L 65.14L 28Cr
Net income	-1.13Cr -80.16L -71.89L -65.7L -59.98L -75Cr -1.17Cr -7.92Cr -3.16Cr -40Cr -3.01Cr -2.94Cr -126.92Cr	-1.39Cr -98.6L -88.43L -80.82L -73.78L -93Cr -1.43Cr -9.74Cr -3.88Cr -49Cr -3.7Cr -3.62Cr -156.12Cr
Net Debt	-	-